These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 3018324)

  • 1. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 2. The treatment of hairy cell leukemia (HCL) with pentostatin (2'-deoxycoformycin, dCF).
    Spiers AS; Parekh SJ
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():173-5. PubMed ID: 2653498
    [No Abstract]   [Full Text] [Related]  

  • 3. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
    Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
    Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
    Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
    Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
    Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
    Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 7. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 8. Production of 2'-deoxycoformycin by the fungus Emericella nidulans and its inhibitory effect on adenosine deaminase.
    Kanbe T; Endo A; Hashizume T
    Nucleic Acids Symp Ser; 1983; (12):115-8. PubMed ID: 6607458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin (2'deoxycoformycin) for the treatment of lymphoid neoplasms.
    Ho AD; Thaler J; Willemze R; Lauria F; Derossi G; Kuse R; Stryckmans P; Blanc CM; Cataldo F; McVie G
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():60-2. PubMed ID: 2653520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
    Earle MF; Glazer RI
    Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Macdonald JS; Marsoni S; Bruno S; Poster D
    Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting biochemical differences in leukemia.
    Coleman MS; Grever MR
    Adv Exp Med Biol; 1984; 165 Pt B():315-20. PubMed ID: 6609538
    [No Abstract]   [Full Text] [Related]  

  • 14. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
    Webster HK; Wiesmann WP; Pavia CS
    Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
    [No Abstract]   [Full Text] [Related]  

  • 15. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
    Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
    J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
    [No Abstract]   [Full Text] [Related]  

  • 17. The activity of deoxycoformycin (pentostatin) in refractory leukemias and lymphomas.
    Spiers AS
    Ann N Y Acad Sci; 1985; 451():138-41. PubMed ID: 3878115
    [No Abstract]   [Full Text] [Related]  

  • 18. Genetic deficiencies of adenosine deaminase and purine nucleoside phosphorylase and their implications for therapy of leukemias.
    Hirschhorn R; Ratech H
    Curr Top Hematol; 1983; 4():1-35. PubMed ID: 6413135
    [No Abstract]   [Full Text] [Related]  

  • 19. Response to deoxycoformycin in T cell leukaemias.
    Catovsky D; Dearden C
    Br Med J (Clin Res Ed); 1988 Jan; 296(6618):356. PubMed ID: 2894233
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.